Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6014451

CCc1cc(OC)c(Br)cc1OC.N

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 13/20 0.61
TAAR1 Q96RJ0 5/20 0.61
HTR2C P28335 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23326110 0.98 HTR2A (0.63) HTR2ATAAR1HTR2C
SCHEMBL29775403 0.98 HTR2A (0.63) HTR2ATAAR1HTR2C
SCHEMBL4474987 0.89 HTR2A (0.53) HTR2ATAAR1HTR2C
SCHEMBL23326239 0.86 HTR2A (0.51) HTR2ATAAR1HTR2C
SCHEMBL23326208 0.86 HTR2A (0.51) HTR2ATAAR1HTR2C
SCHEMBL14565417 0.85 TAAR1 (0.57) HTR2ATAAR1HTR2C
SCHEMBL2949402 0.84 TAAR1 (0.71) HTR2ATAAR1HTR2C
SCHEMBL13753907 0.83 SMN1; SMN2 (0.57) HTR2ATAAR1HTR2C
SCHEMBL31285025 0.82 HTR2A (0.47) HTR2ATAAR1HTR2C
SCHEMBL31520294 0.82 HTR2A (0.72) HTR2ATAAR1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7078406-B2 Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. (US) 2006-07-18 US disclosed
US-20040248851-A1 Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes Life Technologies Corporation 2004-12-09 US disclosed
US-6815445-B2 FOR USE AS FLUORESCENCE DYES AND PROBES Life Technologies Corporation 2004-11-09 US disclosed
EP-1442027-A1 SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2004-08-04 EP disclosed
US-20030105111-A1 Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-06-05 US disclosed
WO-2003031419-A1 SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248851-A1 Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes DHFR, FPR1, CYP1A1 HTR2A 2034/4885TAAR1 2085/4885HTR2C 1658/4885
US-20030105111-A1 Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes DHFR, FPR1, CYP1A1 HTR2A 2034/4885TAAR1 2085/4885HTR2C 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.